Story thread · 2 reports / 2 sources
Oncolytics Biotech® Aligns with FDA on Registrational Path for Second-Line RAS-Mutant MSS Colorectal Cancer
financialpost.com · 3h · first report
FDA written feedback provides alignment on a potential pivotal Part B expansion of the ongoing REO 033 study Proposed pathway offers potential accelerated approval based on objective response rate and progression-free survival supporting full approval Pivotal expansion to follow initial clinical data from the ongoing randomized Part A SAN DIEGO, Aug. 18, 2026 (GLOBE NEWSWIRE) […]
The coverage
- Oncolytics receives FDA feedback on colorectal cancer study design
investing.com · 3h
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.